We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax to Report First-Quarter Earnings: Is a Beat in Store?
Read MoreHide Full Article
We expect Novavax (NVAX - Free Report) to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell. The company’s earnings beat estimates by 32% in the last reported quarter.
The Zacks Consensus Estimate for sales is pegged at $71.84 million, while that for earnings is pinned at 19 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)
Factors Shaping NVAX’s Upcoming Results
Starting this year, pharma giant Sanofi (SNY - Free Report) acquired exclusive rights to market the company’s protein-based COVID-19 vaccine globally (except in certain countries where Novavax has existing partnership agreements). This is part of the company’s recently signed multi-billion-dollar deal, wherein Sanofi assumed commercial responsibility for the vaccine. Based on this transfer of rights, we do not expect Novavax to record product sales from its COVID-19 vaccine.
We expect the company to provide an update on the technology transfer (related to its COVID-19 vaccine) to Sanofi, as well as the transfer of marketing authorizations in the United States and Europe. The company is eligible to receive certain milestone payments from SNY on the completion of these events.
Last December, Novavax started the phase III study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates. This study is comparing the immunogenicity and safety of the CIC vaccine with separate administrations of Novavax’s currently authorized COVID-19 vaccine and a licensed seasonal influenza vaccine. It is also assessing the immunogenicity and safety of the standalone influenza vaccine. Investors would be interested in seeking updates from the company on this study’s progress.
They would also seek an update from Novavax on the progress of its preclinical pipeline, which includes vaccines for RSV and H5N1 bird flu. Novavax is also advancing core technology for different uses, like mucosal vaccination and high-density nanoparticles. It intends to focus on exploring RSV-combination options and new opportunities in diseases like varicella-zoster virus (shingles) and Clostridium difficile (C. Diff.) colitis. The company is also planning to expand into the field of oncology.
NVAX’s Earnings Surprise History
The biotech firm’s earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 0.48%.
Novavax’s shares have lost 20% year to date compared with the industry’s 3% decline.
Image Source: Zacks Investment Research
What Our Model Predicts for NVAX
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some other biotech stocks that have the right combination of elements to beat on earnings this reporting cycle:
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #1 at present.
CytomX Therapeutics’ shares have plunged 22% year to date. CytomXbeat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #3 at present.
argenx stock gained 6% in the year-to-date period. It beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%. ARGX is set to report earnings on May 8, before market open.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Novavax to Report First-Quarter Earnings: Is a Beat in Store?
We expect Novavax (NVAX - Free Report) to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell. The company’s earnings beat estimates by 32% in the last reported quarter.
The Zacks Consensus Estimate for sales is pegged at $71.84 million, while that for earnings is pinned at 19 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)
Factors Shaping NVAX’s Upcoming Results
Starting this year, pharma giant Sanofi (SNY - Free Report) acquired exclusive rights to market the company’s protein-based COVID-19 vaccine globally (except in certain countries where Novavax has existing partnership agreements). This is part of the company’s recently signed multi-billion-dollar deal, wherein Sanofi assumed commercial responsibility for the vaccine. Based on this transfer of rights, we do not expect Novavax to record product sales from its COVID-19 vaccine.
We expect the company to provide an update on the technology transfer (related to its COVID-19 vaccine) to Sanofi, as well as the transfer of marketing authorizations in the United States and Europe. The company is eligible to receive certain milestone payments from SNY on the completion of these events.
Last December, Novavax started the phase III study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates. This study is comparing the immunogenicity and safety of the CIC vaccine with separate administrations of Novavax’s currently authorized COVID-19 vaccine and a licensed seasonal influenza vaccine. It is also assessing the immunogenicity and safety of the standalone influenza vaccine. Investors would be interested in seeking updates from the company on this study’s progress.
They would also seek an update from Novavax on the progress of its preclinical pipeline, which includes vaccines for RSV and H5N1 bird flu. Novavax is also advancing core technology for different uses, like mucosal vaccination and high-density nanoparticles. It intends to focus on exploring RSV-combination options and new opportunities in diseases like varicella-zoster virus (shingles) and Clostridium difficile (C. Diff.) colitis. The company is also planning to expand into the field of oncology.
NVAX’s Earnings Surprise History
The biotech firm’s earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 0.48%.
Novavax, Inc. Price and EPS Surprise
Novavax, Inc. price-eps-surprise | Novavax, Inc. Quote
Novavax’s shares have lost 20% year to date compared with the industry’s 3% decline.
Image Source: Zacks Investment Research
What Our Model Predicts for NVAX
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Novavax has an Earnings ESP of +495.75% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
Here are some other biotech stocks that have the right combination of elements to beat on earnings this reporting cycle:
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #1 at present.
CytomX Therapeutics’ shares have plunged 22% year to date. CytomXbeat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #3 at present.
argenx stock gained 6% in the year-to-date period. It beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%. ARGX is set to report earnings on May 8, before market open.